BioAge Labs to Present at Jefferies London Healthcare Conference
BioAge Labs (Nasdaq: BIOA), a clinical-stage biopharmaceutical company focused on developing therapeutics for metabolic diseases through aging biology, has announced its participation in the Jefferies London Healthcare Conference. CEO and co-founder Kristen Fortney, PhD, will deliver a presentation at the conference, scheduled for November 19-21, 2024. The presentation will be available on-demand, with a live webcast scheduled for November 19 at 1:00-1:25 PM GMT. Interested parties can access the presentation replay through BioAge's investor relations website for approximately 30 days post-conference.
BioAge Labs (Nasdaq: BIOA), una compagnia biofarmaceutica in fase clinica che si concentra sullo sviluppo di terapie per le malattie metaboliche attraverso la biologia dell'invecchiamento, ha annunciato la sua partecipazione alla Conferenza Sanitaria di Jefferies a Londra. Il CEO e co-fondatore Kristen Fortney, PhD, terrà una presentazione durante la conferenza, programmata per il 19-21 novembre 2024. La presentazione sarà disponibile on-demand, con una diretta web in programma per il 19 novembre dalle 13:00 alle 13:25 GMT. Le parti interessate possono accedere alla registrazione della presentazione tramite il sito delle relazioni con gli investitori di BioAge per circa 30 giorni dopo la conferenza.
BioAge Labs (Nasdaq: BIOA), una compañía biofarmacéutica en etapa clínica centrada en desarrollar terapias para enfermedades metabólicas a través de la biología del envejecimiento, ha anunciado su participación en la Conferencia de Salud de Jefferies en Londres. La CEO y cofundadora Kristen Fortney, PhD, realizará una presentación en la conferencia, programada para el 19-21 de noviembre de 2024. La presentación estará disponible bajo demanda, con una transmisión en vivo programada para el 19 de noviembre de 1:00 a 1:25 PM GMT. Las partes interesadas pueden acceder a la repetición de la presentación a través del sitio web de relaciones con inversores de BioAge durante aproximadamente 30 días después de la conferencia.
바이오에이지 연구소 (Nasdaq: BIOA)는 노화 생물학을 통한 대사 질환 치료제를 개발하는 데 주력하는 임상 단계의 생명공학 회사로서, 제퍼리스 런던 헬스케어 컨퍼런스에 참가한다고 발표했습니다. CEO이자 공동 창립자 크리스틴 포트니, PhD가 2024년 11월 19일부터 21일까지 예정된 컨퍼런스에서 발표를 할 예정입니다. 이 발표는 주문형으로 제공되며, 11월 19일 오후 1시부터 1시 25분 GMT까지 생중계가 예정되어 있습니다. 관심 있는 당사자들은 BioAge의 투자자 관계 웹사이트를 통해 컨퍼런스 후 약 30일 동안 발표 녹화에 접근할 수 있습니다.
BioAge Labs (Nasdaq: BIOA), une société biopharmaceutique en phase clinique axée sur le développement de thérapies pour les maladies métaboliques à travers la biologie du vieillissement, a annoncé sa participation à la Conférence Healthcare de Jefferies à Londres. La PDG et co-fondatrice Kristen Fortney, PhD, fera une présentation lors de la conférence, prévue du 19 au 21 novembre 2024. La présentation sera disponible à la demande, avec une diffusion en direct prévue le 19 novembre de 13h00 à 13h25 GMT. Les parties intéressées peuvent accéder à la rediffusion de la présentation via le site Internet des relations investisseurs de BioAge pendant environ 30 jours après la conférence.
BioAge Labs (Nasdaq: BIOA), ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf die Entwicklung von Therapeutika für Stoffwechselkrankheiten über die Altersbiologie konzentriert, hat seine Teilnahme an der Jefferies London Healthcare Conference angekündigt. CEO und Mitgründer Kristen Fortney, PhD wird auf der Konferenz, die für den 19. bis 21. November 2024 geplant ist, eine Präsentation halten. Die Präsentation wird auf Abruf verfügbar sein, mit einem Live-Webcast, der für den 19. November von 13:00 bis 13:25 GMT angesetzt ist. Interessierte können die Aufzeichnung der Präsentation über die Investor-Relations-Website von BioAge etwa 30 Tage nach der Konferenz abrufen.
- None.
- None.
RICHMOND, Calif., Oct. 24, 2024 (GLOBE NEWSWIRE) -- BioAge Labs (Nasdaq: BIOA) (“BioAge”), a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging, today announced that Kristen Fortney, PhD, CEO and co-founder, will present at the Jefferies London Healthcare Conference, which takes place November 19–21, 2024.
The on-demand presentation will be available from through the conference site. To access the live webcast of the presentation (1:00-1:25 PM GMT on November 19), please register here. An archived replay of the webcast will be available through the Investors section of the BioAge website https://ir.bioagelabs.com for approximately 30 days following the conference.
About BioAge Labs, Inc.
BioAge is a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases, such as obesity, by targeting the biology of human aging. BioAge’s lead product candidate, azelaprag, is an orally available small molecule agonist of APJ that was observed to promote metabolism and prevent muscle atrophy on bed rest in a Phase 1b clinical trial. In mid-2024, BioAge initiated a Phase 2 trial of azelaprag in combination with tirzepatide for the treatment of obesity in older adults. Azelaprag has potential as an oral regimen to amplify weight loss and improve body composition in patients on obesity therapy with incretin drugs. BioAge is also developing orally available small molecule brain penetrant NLRP3 inhibitors for the treatment of diseases driven by neuroinflammation. BioAge’s preclinical programs, based on novel insights from the company’s discovery platform built on human longevity data, address key pathways in metabolic aging.
Contacts
PR: Chris Patil, media@bioagelabs.com
IR: Elena Liapounova, ir@bioagelabs.com
Partnering: partnering@bioagelabs.com
Web: https://bioagelabs.com
FAQ
When is BioAge Labs (BIOA) presenting at the Jefferies London Healthcare Conference 2024?
How long will BioAge Labs' (BIOA) Jefferies conference presentation be available for replay?
What is the focus area of BioAge Labs' (BIOA) therapeutic development?
Where can investors access BioAge Labs' (BIOA) Jefferies conference presentation replay?
